In focus · trending topic

Special Protocol Assessment

1 stories · following the connections

Asklepion Pharmaceuticals Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Program of Intravenous Citrulline

By Nasdaq OMXDec 19, 2017, 2:01 PM UTC